IWM
TRDA icon

IHT Wealth Management’s Entrada Therapeutics TRDA Stock Holding History

IHT Wealth Management’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,100
Closed -$140K – 1349
2026
Q1 		$140K Hold
11,100
– – ﹤0.01% 1214
2025
Q4 		$114K Hold
11,100
– – ﹤0.01% 1152
2025
Q3 		$64.4K Buy
11,100
+400
+4% +$2.34K ﹤0.01% 1150
2025
Q2 		$71.9K Buy
+10,700
New +$86.1K ﹤0.01% 1126

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

IHT Wealth Management's TRDA Position: Q2 2026 in Review

IHT Wealth Management sold out of Entrada Therapeutics (TRDA) in Q2 2026, closing a stake of 11,100 shares — an estimated $140K sold.

IHT Wealth Management first reported a position in TRDA in Q2 2025 and held it in 4 quarters. The position peaked at $140K in Q1 2026. 128 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • IHT Wealth Management reported no remaining Entrada Therapeutics position as of Q2 2026 after selling out during the quarter.
  • IHT Wealth Management sold 11,100 Entrada Therapeutics shares in Q2 2026, an estimated $140K.
  • IHT Wealth Management first reported a position in Entrada Therapeutics in Q2 2025 and held it in 4 quarters.
  • IHT Wealth Management's Entrada Therapeutics position peaked at $140K in Q1 2026.
  • 128 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on IHT Wealth Management's 13F filing for Q2 2026, filed 14 Aug 2026.